Trial · NCT06582446
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
NCT06582446, Phase 2, Recruiting, German Oncology Center, Cyprus
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial). Trials, record NCT06582446. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06582446
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
- NCT number
- NCT06582446
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- German Oncology Center, Cyprus
- Conditions
- Prostate Cancer
- Interventions
- Androgen Deprivation Therapy (ADT) - Goserelin, High-Dose-Rate Interstitial Brachytherapy (HDR BRT), radiotherapy
- First posted
- 2024-09-03
- Last updated
- 2026-09-17
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | cumulative GU toxicity | two years | Primary endpoint is cumulative GU toxicity according to RTOG grading after minimum FU time of two years. |
| Secondary | Time to local or regional failure | two and five years after RT | Time to local or regional failure; after end of RT. Local or regional recurrences have to be confirmed by PSMA-PET or mpMR imaging. For the diagnosis of local failure a verification via biopsy is warranted. |
| Secondary | MMAI classifier | 5-year and 10-year risk prediction of distant metastasis and 10-year risk of prostate-specific mortality. | Prognostic influence of MMAI classifier for outcome; the ArteraAI Prostate Test score (ranging from 0.0 to 1.0) |
| Secondary | Testosterone | assessment at 6,9,12,18 and 24 months after randomization (± 14 days for each visit) and at 30, 36, 42, 48, 54, 60 months after Ultra-hypofractionated RT - UHF (± 1 month | Testosterone recovery is to be done through blood test |
| Secondary | Metastatic free survival (MFS) | two and five years after RT | MFS after end of RT, (all metastases have to be confirmed by PSMA-PET/CT or mpMR imaging) |
| Secondary | Overall Survival (OS) | 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after RT | OS after end of RT |
| Secondary | Prostate cancer specific survival (PCSS) | 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after RT | PCSS after end of RT |
| Secondary | Biochemical failure | two and five years after RT | Time to biochemical failure after end of RT (phoenix definition) |
| Secondary | Quality of Life (QoL) | Assessments at 6, 9,12, 18, and 24 months after randomization (± 14 days for each visit) and at 30, 36, 42, 48, 54, 60 months after Ultra-hypofractionated RT - UHF (± 1 month) | Patient-reported outcome measures (PROMs) EPIC-26: the Expanded Prostate Cancer Index-Short form) with score: 0-100 |
| Secondary | QoL | Assessments at 6, 9,12, 18, and 24 months after randomization (± 14 days for each visit) and at 30, 36, 42, 48, 54, 60 months after Ultra-hypofractionated RT - UHF (± 1 month) | Patient-reported outcome measures (PROMs) IIEF-5: The International Index of Erectile Function with score: 0-5 |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40645505 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06582446
GET https://conductscience.org/api/trials/v1/NCT06582446/registered?page=2